DNTH
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Dianthus Therapeutics introduced DNTH312, a next-generation bifunctional fusion protein for severe autoimmune diseasesAug 4, 2026
- Dianthus Therapeutics initiated the Phase 3 EMERGE trial of Claseprubart for generalized myasthenia gravisJun 29, 2026
- LBL-047 was prioritized for clinical development in multiple autoimmune diseasesMay 6, 2026
- Dianthus Therapeutics announces exclusive license agreement with Leads Biolabs for DNTH212, a first and potentially best-in-class, Phase 1 ready bifunctional BDCA2 & BAFF/APRIL inhibitor for severe autoimmune diseasesOct 16, 2025
- Dianthus Therapeutics announces positive data for Claseprubart (DNTH103) from Phase 2 MaGic trial in generalized myasthenia gravis supporting best-in-class potentialSep 8, 2025